Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit grows, but more slowly than its trailing trend

Q3 FY2026 gross profit of $73.44M rose 153.4% year over year, behind the +169.7% change in trailing-twelve-month gross profit. Sequentially, it rose 31.8% from the prior quarter.

Context

  • Gross profit amounted to 34.3% of revenue in FY2025, up 9.9 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +153.4% toward the trailing-twelve-month pace of +169.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$73.44M+31.8% QoQ
Last fiscal yearDec 2025
$90.32M+125.4% YoY
LTMSep 2026
$201.75M+169.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+153.4%——
1 year+125.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
90.32M USD
Year-over-year change
+125.4%

Gross Profit vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +169.7% is the highest of 9, against a peer median of +36.2%.
  • Gross profit amounts to 53.2% of revenue for IOVA, versus a peer median of 93.0%.
IOVA Competitors
Gross Profit for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$3.84B USD—-38.3%93.0%
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$201.75M USD+169.7%—53.2%
IBRXImmunityBio, Inc.LTM Sep 2026$176.5M USD+125.6%+676.9%96.7%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
REPLReplimune Group, Inc.LTM Dec 2025-$848K USD———
FATEFate Therapeutics, Inc.LTM Mar 2026-$26.26M USD+63.7%—415.8%
Peer median (excluding IOVA) —+36.2%+28.0%93.0%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.